pharmaphorum7d
Ten years on, Roche jettisons InterMune and Esbriet in US
Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...
pharmaphorum13d
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Business Insider19d
Roche Holdings Inc.DL-Notes 2021(21/28) Reg.S Bond
The Roche Holdings Inc.-Bond was issued on the 12/13/2021 with a volume of 2 B. USD. Indices Commodities Currencies Stocks ...
FiercePharma11d
Roche details Gazyva's positive data en route to key lupus nephritis expansion
While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...
Business Insider19d
Roche Holdings Inc.DL-Notes 2021(21/51) 144A Bond
More Bonds of Roche Holdings Inc. Moody’s Daily Credit Risk Score About the Roche Holdings Inc.-Bond (US771196BY74) The Roche Holdings Inc.-Bond has a maturity date of 12/13/2051 and offers a ...
PharmiWeb13d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...